Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up
Proteome insights of citric acid-mediated cadmium toxicity tolerance in brassica napus l
No superar la dosis diaria recomendada y mantener en un lugar fresco y seco lejos de nios pequeos
As a Growth Hormone-Releasing Peptide (GHRP) , Ipamorelin supports lean muscle development, enhances fat metabolism, and promotes cellular regenerationmaking it an ideal therapy for those seeking a natural, non-invasive approach to wellness, recovery, and anti-aging
doi: 10.1016/j.cell.2010.03.014 29 GeeraertsXet al
Lu : Thng tin ny ch mang tnh cht tham kho
